Skip to main content

Third Wave's Q3 Revenues Grow 24 Percent, Loss Rises

NEW YORK (GenomeWeb News) — Third Wave Technologies today said third-quarter revenues grew 24 percent as R&D spending rose 68 percent and its net loss widened 25 percent. 
Total receipts for the three months ended Sept. 30 increased to $8.2 million from $6.6 million year over year.
Revenue from clinical products rose 25 percent to $6.7 million, while receipts from research products increased 19 percent to $1.4 million.
The firm’s R&D expenses rose to $5.8 million from $3.5 million the previous year.
Third Wave’s net loss for the period swelled to $6.4 million from $5.2 million year over year, due in part to $1.8 million in litigation charges during the quarter.
The firm is locked in an ongoing patent and antitrust dispute with Digene, which recently was acquired by Qiagen.
Third Wave had around $43.6 million in cash, cash equivalents, and short-term investments as of Sept. 30.
The company also reaffirmed its previously announced guidance of 2007 clinical molecular diagnostics revenue of $26 million to $28 million and total revenue of $31 million to $33 million.
"We believe Third Wave is well positioned to create a sustainable competitive advantage through unique HPV products and an automated instrument offering, and through leadership in the rapidly-growing hospital laboratory market,” Third Wave President and CEO Kevin Conroy said in a statement.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.